tiprankstipranks
Kronox Lab Sciences Limited (IN:KRONOX)
:KRONOX
India Market
Want to see IN:KRONOX full AI Analyst Report?

Kronox Lab Sciences Limited (KRONOX) AI Stock Analysis

0 Followers

Top Page

IN:KRONOX

Kronox Lab Sciences Limited

(KRONOX)

Select Model
Select Model
Select Model
Outperform 79 (OpenAI - Gpt-5.6Sol)
Rating:79Outperform
Price Target:
₹198.00
▲(48.66% Upside)
Action:Reiterated
Date:08/26/26
Overall score reflects strong financial quality (high profitability, low leverage, solid free cash flow) and a clear positive technical trend (price above major moving averages with supportive momentum). The main constraint is valuation, with a higher P/E and minimal dividend yield, plus some caution from the latest-year cash flow decline.
Positive Factors
Profitability
Rising net income and a high reported net margin indicate that Kronox converts revenue into earnings efficiently. Strong profitability can support internal funding, reinforce resilience through normal business fluctuations, and provide capacity to invest in future growth over the coming quarters.
Negative Factors
Limited Revenue Growth
Near-flat reported revenue suggests that Kronox has not yet demonstrated consistent top-line expansion. Without stronger demand growth, future earnings increases may rely more heavily on margin performance, limiting operating leverage and reducing the durability of profit growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability
Rising net income and a high reported net margin indicate that Kronox converts revenue into earnings efficiently. Strong profitability can support internal funding, reinforce resilience through normal business fluctuations, and provide capacity to invest in future growth over the coming quarters.
Read all positive factors

Kronox Lab Sciences Limited (KRONOX) vs. iShares MSCI India ETF (INDA)

Kronox Lab Sciences Limited Business Overview & Revenue Model

Company Description
Kronox Lab Sciences Ltd. operates as a manufacturer and global supplier of a diverse range of chemical products, encompassing fine chemicals, inorganic compounds, phosphates, and metallic chemicals, serving markets both within India and worldwide....

Kronox Lab Sciences Limited Financial Statement Overview

Summary
Strong profitability and margins with net income rising (FY2026: 276.6m vs FY2025: 254.7m), a conservatively levered balance sheet (very low debt vs equity), and solid free cash flow generation. Offsets include declining operating/free cash flow in FY2026 and unclear growth consistency due to conflicting revenue growth signals.
Income Statement
86
Very Positive
Balance Sheet
83
Very Positive
Cash Flow
78
Positive
BreakdownTTMMar 2025Mar 2024
Income Statement
Total Revenue1.05B1.01B1.00B
Gross Profit540.21M546.44M492.71M
EBITDA395.08M394.65M356.53M
Net Income285.70M276.60M254.67M
Balance Sheet
Total Assets0.001.28B988.26M
Cash, Cash Equivalents and Short-Term Investments487.41M487.41M358.73M
Total Debt0.0016.07M0.00
Total Liabilities-1.16B113.96M87.22M
Stockholders Equity1.16B1.16B901.05M
Cash Flow
Free Cash Flow74.67M205.85M275.92M
Operating Cash Flow104.97M238.93M306.97M
Investing Cash Flow-116.43M-238.20M-283.94M
Financing Cash Flow7.61M-3.62M-18.54M

Kronox Lab Sciences Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price133.19
Price Trends
50DMA
164.38
Positive
100DMA
151.68
Positive
200DMA
139.62
Positive
Market Momentum
MACD
3.54
Positive
RSI
49.05
Neutral
STOCH
21.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KRONOX, the sentiment is Neutral. The current price of 133.19 is below the 20-day moving average (MA) of 178.73, below the 50-day MA of 164.38, and below the 200-day MA of 139.62, indicating a neutral trend. The MACD of 3.54 indicates Positive momentum. The RSI at 49.05 is Neutral, neither overbought nor oversold. The STOCH value of 21.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:KRONOX.

Kronox Lab Sciences Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
₹6.41B22.220.29%6.07%11.62%
67
Neutral
₹5.68B19.080.49%11.71%79.88%
62
Neutral
₹3.14B20.611.34%3.55%-21.35%
61
Neutral
₹4.53B12.710.39%-0.60%96.35%
60
Neutral
₹2.97B20.750.88%-26.36%-55.59%
55
Neutral
$6.65B3.83-15.92%6.20%10.91%7.18%
49
Neutral
₹4.12B19.230.26%17.28%-10.19%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:KRONOX
Kronox Lab Sciences Limited
172.90
>-0.01
>-0.01%
IN:ASAHISONG
Asahi Songwon Colors Ltd.
380.10
92.90
32.35%
IN:CHEMBOND
Chembond Chemicals Limited
225.30
42.83
23.48%
IN:DICIND
DIC India Limited
600.35
36.99
6.57%
IN:MANORG
Mangalam Organics Ltd
460.65
-94.35
-17.00%
IN:PODDARMENT
Poddar Pigments Limited
300.05
16.02
5.64%

Kronox Lab Sciences Limited Corporate Events

Kronox Lab Sciences Sets September Date for 17th AGM via Virtual Format
Aug 30, 2026
Kronox Lab Sciences Limited operates in the laboratory chemicals and scientific supplies sector, serving industrial and research clients through its portfolio of high-purity reagents and related lab products. The company is listed on both the Nati...
Kronox Lab Sciences Sets September 16 AGM, Proposes Dividend and Cost Audit Pay
Aug 24, 2026
Kronox Lab Sciences Limited has scheduled its 17th Annual General Meeting for September 16, 2026, at 11:00 a.m., to be conducted via video conferencing and other audio-visual means in line with recent regulatory guidance. The company has circulate...
Indo Borax launches open offer for public shareholders of Kronox Lab Sciences
Aug 21, 2026
Kronox Lab Sciences Limited has disclosed that it has received a public announcement for an open offer to its public shareholders, triggered under India’s takeover regulations. The offer is being made by Indo Borax Chemicals Limited, togeth...
Kronox Promoters Agree to Sell Majority Stake to Indo Borax
Aug 20, 2026
Promoters of Kronox Lab Sciences Limited have signed a share purchase agreement to sell 2,38,44,000 equity shares, representing about 64.26% of the company’s paid-up equity capital, to Indo Borax Chemicals Limited, with Zenrock Chemicals Pr...
Kronox Lab Sciences Publishes Q1 FY2026 Unaudited Results in Newspapers
Aug 16, 2026
Kronox Lab Sciences Limited has notified the National Stock Exchange of India and BSE that it has published its unaudited financial results for the quarter ended June 30, 2026 in the Indian Express and Financial Express newspapers. The disclosure,...
Kronox Lab Sciences Files SEBI Compliance Certificate on Demat Activities
Jul 5, 2026
Kronox Lab Sciences Limited has submitted to the National Stock Exchange of India and BSE a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026. The certif...
Kronox Lab Sciences to Close Trading Window Ahead of Q1 Results
Jun 25, 2026
Kronox Lab Sciences Limited has announced that its trading window for dealing in the company’s equity shares will be closed for all designated persons starting 1 July 2026, in line with SEBI’s Prohibition of Insider Trading Regulations...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 26, 2026